Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2006
Business Overview: Repligen is a biopharmaceutical company developing novel therapeutics for central nervous system diseases (schizophrenia, bipolar disorder) while maintaining a commercial business manufacturing Protein A (for monoclonal antibody purification) and SecreFlo (for pancreatic diagnosis). The company's strategy involves funding therapeutic development through profits from commercial products.
Key Financial Metrics
| Metric | Fiscal 2006 | Fiscal 2005 | Fiscal 2004 |
|---|---|---|---|
| Total Revenue | $12,911,000 | $9,360,000 | $6,914,000 |
| Net Income (Loss) | $697,000 | $(2,984,000) | $(9,551,000) |
| Operating Income (Loss) | $(1,220,000) | $(4,162,000) | $(9,941,000) |
| Research & Development | $5,163,000 | $5,037,000 | $6,484,000 |
| Cash & Marketable Securities | $23,408,000 | $23,523,000 | $24,269,000 |
| Working Capital | $18,575,000 | $15,673,000 | $13,684,000 |
| Long-term Obligations | $231,000 | $120,000 | $86,000 |
Note: Net income for 2006 includes a significant non-recurring "Other Income" item of $1.17 million related to a legal settlement.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 38% year-over-year, driven primarily by a 48% increase in Protein A sales ($10.54M vs $7.13M) due to expanded supply agreements with GE Healthcare. SecreFlo sales declined 9% to $1.99M.
- Profitability: The company returned to profitability with a net income of $697,000, compared to a net loss of $2.98M in 2005. This turnaround was significantly aided by a $1.17M reversal of accrued royalties (recorded as Other Income) following a settlement with ChiRhoClin.
- Operating Expenses: Total operating expenses rose 5% to $14.13M. Cost of product revenue decreased 9% due to reduced royalty/amortization fees from the ChiRhoClin settlement, offset by higher material costs. SG&A expenses increased 18% due to higher personnel and legal costs.
- Balance Sheet: Cash and marketable securities remained stable at approximately $23.4M. Working capital improved to $18.6M.
Guidance, Outlook, and Risks
- Outlook: Management expects Protein A sales to continue growing in fiscal 2007, though at a reduced rate. R&D expenses are expected to increase due to expanded clinical trials (specifically for uridine in bipolar depression and secretin for MRI imaging). SG&A is projected to rise due to ongoing litigation and personnel costs.
- Liquidity: The company believes current cash balances are adequate to meet needs for at least the next 24 months absent an acquisition. No dividends are anticipated.
- Legal Proceedings:
- Bristol-Myers Squibb: Repligen sued BMS in Jan 2006 for patent infringement regarding the drug Orencia (CTLA4-Ig). BMS counterclaimed seeking a declaratory judgment of invalidity.
- ImClone Systems: Ongoing litigation regarding patent infringement for Erbitux. Summary judgment motions were heard in Feb 2006; outcome remains undetermined.
- ChiRhoClin: Arbitration settled in May 2005. Repligen secured continued supply of SecreFlo and favorable royalty terms.
- Risks: Dependence on single suppliers (ChiRhoClin for SecreFlo), reliance on third-party manufacturers, uncertainty of clinical trial outcomes, and potential inability to raise additional capital if development costs exceed projections.
- Accounting Changes: The company plans to adopt SFAS No. 123(R) on April 1, 2006, which is expected to result in approximately $810,000 of additional stock-based compensation expense in fiscal 2007.
Investor Verification Checklist
- Non-Recurring Income: Verify the sustainability of the 2006 net profit by excluding the $1.17M one-time royalty reversal from the ChiRhoClin settlement.
- Customer Concentration: Confirm the status of the supply agreement with GE Healthcare, which accounted for approximately 49% of total revenue in 2006.
- Legal Exposure: Monitor the status of the patent infringement lawsuits against Bristol-Myers Squibb and ImClone Systems, as adverse outcomes could impact future royalty revenue streams.
- Supplier Risk: Assess the timeline for the depletion of SecreFlo supplies from ChiRhoClin, after which Repligen will cease marketing this product.
- Future Expenses: Review the projected impact of SFAS 123(R) adoption on future earnings, estimated at $810,000 for fiscal 2007.